Skip to content

CG Oncology CGON Change in AR

Change in AR at other companies

Pfizer logo
PfizerPFE
$65.75M+141%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$595M-35.7%
Gilead Sciences logo
Gilead SciencesGILD
-$134M-69.6%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$700K-95.2%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
-$563K-562%
Exelixis logo
ExelixisEXEL
$42.03M+161%

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.39B+206%
Enterprise value$5.36B+212%
P/S1,062.4×-1,596×

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's change in AR?
CG Oncology (CGON) reported change in AR of $587K in Q1 2026.
What does change in AR mean?
Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.